NCT02665234View on ClinicalTrials.gov

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

March 31, 2017

Conditions
Keratoconjunctivitis Sicca
Interventions
DRUG

1% Tavilermide Ophthalmic Solution

1% Tavilermide BID Dosing

DRUG

Placebo Ophthalmic Solution

Vehicle Ophthalmic Solution

Trial Locations (1)

Unknown

MIM-726 Investigational Site, Torrance

Sponsors
All Listed Sponsors
lead

Mimetogen Pharmaceuticals USA, Inc.

INDUSTRY